TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Positive predictive value for DMARD-start
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CA 27.29 levels after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily intravenous morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slope of the carbon dioxide response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: minute ventilation at P(ET)CO2 = 50 mmHg (VE50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of major or minor bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Composite star ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Negative comments on health system websites
Endpoint domain: Adverse events/effects
Primary endpoint: Giardia infection prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of pulmonary exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Event-free survival (EFS) at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: ED stay duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean PBH number per patient at year 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of NL evolving into PBH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stain composite score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotation stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprotected intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated HIV transmission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Topographic astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal obesity prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breakthrough seizure risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Seizure recurrence risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 12-month remission achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 30-second STST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-minute STST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IPSS at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of anejaculation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing persistent Clavien‐Dindo grade 1 or higher adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3, 4, or 5 treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical complete response (cCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of extubation during the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 order rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in FA values in selected association fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Full brow regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ONSD (Optic Nerve Sheath Diameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salt acceptance at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Licking salt from food surfaces at preschool age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative placement disruptions
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: perineal oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perineal bruising
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term exacerbation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: oral corticosteroid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microleakage protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biocompatibility of MTA materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF12-MCS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: LSS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: LOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Event free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Cough reflex sensitivity (C(5))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of primary mental health care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total cardiovascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive ability for death
Endpoint domain: Mortality/survival
Primary endpoint: Mean duration of urinary catheter indwelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Keratocyte density in the anterior stroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratocyte density in the stromal flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratocyte density in the anterior retroablation zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgetic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of infants who attained protective antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distribution of antibody titers against diphtheria toxoid, tetanus toxoid and H. influenzae type b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of infants with detectable neutralizing antibodies against poliovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of absorption of retinal hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal circulation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late Lumen Loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Itch score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global end evaluation (patient)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-y all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: decrease in visual midline shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCORA pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCORA-morphine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patient response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mono-follicular development rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colposcopy finding of any kind
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic finding of any kind
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident HIV cases
Endpoint domain: Adverse events/effects
Primary endpoint: base excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum chloride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite of death, reinfarction or stroke
Endpoint domain: Mortality/survival
Primary endpoint: All-cause death, myocardial infarction, or target lesion thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Odds of pre‐eclampsia/eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Odds of serious infection within 14 days of delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Odds of severe anemia (grade 3 or 4) by 6 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: alcohol outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: violence outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of men obtaining ≥ 60% base and/or tip rigidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to first measured base rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median total duration of recorded base rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of delivered compressions within target depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected logMAR visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of death, myocardial infarction, nonprotocol revascularization or hospital admissions
Endpoint domain: Mortality/survival
Primary endpoint: Ability to recognise expressions of anger and fear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of intestinal peristalsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum MOT and SS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in major hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Improved self-reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Likelihood of lipid testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of action plans
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Instances of spirometry per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cmax and AUC of darexaban glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin time (PT-INR), activated partial thromboplastin time (aPTT), and FXa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCI length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local detachment of Descemet membrane
Endpoint domain: Adverse events/effects
Primary endpoint: Mean gastric endoscopy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reliability and reproducibility of diabetic retinopathy evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to describe an emergency situation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to raise the alert
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of plasma IgA and IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of plasma IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delayed type hypersensitivity (DTH) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial number of duodenal acidic periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of duodenal acidification periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: P3 amplitude to auditory stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P3 amplitude to visual stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of soluble intercellular adhesion molecule‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PORH max response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tp analysis response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported reinjury rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss and return of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-density lipoprotein cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Control over the voices
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety about completing CTCH tasks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for follow-up and ongoing support
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Condom use with a regular partner
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of modern contraception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Received HTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPI of R MAX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of levothyroxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUCt of levothyroxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma asparaginase activity ≥ 100 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma asparaginase activity ≥ 400 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of undetectable plasma asparagine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of nuclear cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Prevalence of posterior subcapsular cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Prevalence of cortical cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Cumulative adverse events to 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: minor wound complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: aesthetic preference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: response rates after 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's percentage weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum negative quadriceps power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient reported pain and function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rotavirus serum IgA seroresponse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum IgA geometric mean concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SGRQ-C non-inferiority
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: TDI total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient global assessment of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual field detection deficit improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: temporal processing of visual stimuli improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of treatment successes (clinically cured or improved)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean difference in utility values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in BMD of the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increase in BMD of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Erosion of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to ischemic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Goitre size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 levels postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: vaginal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores with movement at 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean postoperative hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mydriasis of at least 6 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of nurse gestures per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: decrease of fT4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: decrease of fT3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: success rate for CCC
Endpoint domain: Mortality/survival
Primary endpoint: adequate image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shear stress on the residual limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to insert ProSeal LMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: annual cost increase associated with Katz stage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportions of patients meeting moderate intensity physical activity recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of patients meeting vigorous physical activity recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAQoL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: GDS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of DA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of DA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of SD-1077/CD
Endpoint domain: Adverse events/effects
Primary endpoint: Cost savings per patient treated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Facial grading system improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in synkinesis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin fragment 1.2 (F1.2) mean concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dysmenorrhea symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language-related activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lateralization index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: health care utilisation outcomes
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Plasma levels of oestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes